Inflammation in atherosclerosis as a potential therapeutic target
Authors:
Josef Kořínek 1,2,3; Miloš Dobiáš 3; Michal Vrablík 4
Authors‘ workplace:
II. interní klinika – klinika kardiologie a angiologie 1. LF UK a VFN v Praze
1; II. chirurgická klinika – klinika kardiovaskulární chirurgie 1. LF UK a VFN v Praze
2; Klinika anesteziologie, resuscitace a intenzivní medicíny 1. LF UK a VFN v Praze
3; III. interní klinika 1. LF UK a VFN v Praze
4
Published in:
AtheroRev 2024; 9(3): 119-125
Category:
Reviews
Overview
The pathophysiology of atherosclerosis includes a very important inflammatory component, which participates on the origin and progression of atherosclerosis and moreover on atherosclerotic complications. The importance of chronic low grade systemic inflammation, that very often accompanies atherosclerosis risk factors such as diabetes, obesity smoking and others, has been recently emphasized more frequently. This brief review article addresses some aspects of inflammatory process of atherosclerosis as well as discusses potential possibilities of anti-inflammatory therapy, especially primarily anti-inflammatory drugs and some drugs that have been developed to treat different conditions, however have also anti-inflammatory effects.
Keywords:
Atherosclerosis – inflammation – Key words: anti-inflammatory therapy – interleukin 1 (IL-1) – interleukin 6 (IL-6)
Sources
Vaduganathan M, Mensah GA, Turco JV et al. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol 2022; 80(25): 2361–2371. Dostupné z DOI: <https://doi: 10.1016/j.jacc.2022.11.005>.
Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal 2023; 44(38): 3720–3826. Dostupné z DOI: <https://doi: 10.1093/eurheartj/ehad191>.
Vrints C, Andreotti F, Koskinas KC et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2024; 45(36): 3415–3537. Dostupné z DOI: <https://doi: 10.1093/eurheartj/ehae177>.
Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal 2021; 42(34): 3227–3337. Dostupné z DOI: <https://doi: 10.1093/eurheartj/ehab484>.
Tsalamandris S, Antonopoulos AS, Oikonomou E et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol 2019; 14(1): 50–59. Dostupné z DOI: <https://doi: 10.15420/ecr.2018.33.1>.
Marx N, Federici M, Schütt K et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European Heart Journal 2023; 44(39): 4043–4140. Dostupné z DOI: <https://doi: 10.1093/eurheartj/ehad192>.
Soták M, Clark M, Suur BE et al. Inflammation and resolution in obesity. Nat Rev Endocrinol 2024. Dostupné z DOI: <https://doi: 10.1038/s41574–024–01047-y>.
Domingo E, Marques P, Francisco V et al. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases? Pharmacol Res 2024; 200(10): 107058. Dostupné z DOI: <https://doi: 10.1016/j.phrs.2024.107058>.
Elisia I, Lam V, Cho B et al. The effect of smoking on chronic inflammation, immune function and blood cell composition. Scientific Reports 2020; 10(1): 19480. Dostupné z DOI: <https://doi: 10.1038/s41598–020–76556–7>.
Ishida M, Sakai C, Kobayashi Y et al. Cigarette Smoking and Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb 2024; 31(3): 189–200. Dostupné z DOI: <https://doi: 10.5551/jat.RV22015>.
Attiq A, Afzal S, Ahmad W et al. Hegemony of inflammation in atherosclerosis and coronary artery disease. Eur J Pharmacol 2024; 966: 176338. Dostupné z DOI: <https://doi: 10.1016/j.ejphar.2024.176338>.
Barbu E, Popescu MR, Popescu AC et al. Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging. Int J Mol Sci 2022; 23(2): 963. Dostupné z DOI: <https://doi: 10.3390/ijms23020963>.
Rose-John S, Jenkins BJ, Garbers C et al. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol 2023; 23(10): 666–681. Dostupné z DOI: <https://doi: 10.1038/s41577–023–00856-y>.
Alfaddagh A, Martin SS, Leucker TM et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am J Prev Cardiol 2020; 4: 100130. Dostupné z DOI: <https://doi: 10.1016/j.ajpc.2020.100130>.
Ahlehoff O, Skov L, Gislason G et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273: 197–204. Dostupné z DOI: <https://doi: 10.1111/j.1365–2796.2012.02593.x>.
Naranjo A, Sokka T, Descalzo MA et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10(2): R30. Dostupné z DOI: <https://doi: 10.1186/ar2383>.
Bulgarelli A, Martins Dias AA, Caramelli B et al. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2012; 59(4): 308–314. Dostupné z DOI: <https://doi: 10.1097/FJC.0b013e318241c385>.
Ridker PM, Everett BM, Pradhan A et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med 2019; 380(8): 752–762. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1809798>.
Tardif JC, Kouz S, Waters DD et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019; 381(26): 2497–2505. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1912388>.
Nidorf SM, Fiolet ATL, Mosterd A et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383(19): 1838–1847. Dostupné z DOI: <https://doi: 10.1056/NEJMoa2021372>.
Rakocevic J, Dobric M, Borovic ML et al. Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand? Rev Cardiovasc Med 2023; 24(1): 10. Dostupné z DOI: <https://doi: 10.31083/j.rcm2401010>.
Ridker PM, Everett BM, Thuren T et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377(12): 1119–1131. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1707914>.
Akita K, Isoda K, Sato-Okabayashi Y et al. An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice. Front Cardiovasc Med 2017; 4: 84. Dostupné z DOI: <https://doi: 10.3389/fcvm.2017.00084>.
Broch K, Anstensrud AK, Woxholt S et al. Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol 2021; 77(15): 1845–1855. Dostupné z DOI: <https://doi: 10.1016/j.jacc.2021.02.049>.
Ridker PM, Devalaraja M, Baeres FMM et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021; 397(10289): 2060–2069. Dostupné z DOI: <https://doi: 10.1016/s0140–6736(21)00520–1>.
Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res 2021; 117(11): e138-e140. Dostupné z DOI: <https://doi: 10.1093/cvr/cvab231>.
Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1603827>.
Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519–1529. Dostupné z DOI: <https://doi: 10.1016/s0140–6736(18)32261-x>.
Giugliano D, Longo M, Signoriello S et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol 2022; 21(1): 42. Dostupné z DOI: <https://doi: 10.1186/s12933–022–01474-z>.
Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389(24): 2221–2232. Dostupné z DOI: <https://doi: 10.1056/NEJMoa2307563>.
Mosenzon O, Capehorn MS, De Remigis A et al. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol 2022; 21(1): 172. Dostupné z DOI: <https://doi: 10.1186/s12933–022–01585–7>.
Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab 2024; 15: 20420188231222367. Dostupné z DOI: <https://doi: 10.1177/20420188231222367>.
McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1911303>.
Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387(12): 1089–1098. Dostupné z DOI: <https://doi: 10.1056/NEJMoa2206286>.
Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <https://doi: 10.1056/NEJMoa2022190>.
Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine 2021; 385(16): 1451–1461. Dostupné z DOI: <https://doi: 10.1056/NEJMoa2107038>.
Scisciola L, Cataldo V, Taktaz F et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front Cardiovasc Med 2022; 9: 1008922. Dostupné z DOI: <https://doi: 10.3389/fcvm.2022.1008922>.
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1504720>.
Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137(4): 323–334. Dostupné z DOI: <https://doi: 10.1161/CIRCULATIONAHA.117.032038>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2024 Issue 3
Most read in this issue
- Inflammation in atherosclerosis as a potential therapeutic target
- Eggs: nutritional and health importance for the general population and patients with statin therapy
- 28th Congress on Atherosclerosis, 12th–14th December 2024, Brno
- Statin intolerance in questions and answers